Multiple Sclerosis News

• CMSC 2020Telerehabilitation May Be Effective in MS Telerehabilitation is safe, may offer functional benefits comparable to those of outpatient rehabilitation for patients with MS and impaired mobility, and also saves time and travel costs.
  Medscape Medical News, June 01, 2020
• Constraint Movement Therapy May Boost Neuroplasticity in MS Findings on neuroimaging suggest that for patients with progressive multiple sclerosis, constraint-induced movement therapy leads to changes in white and gray matter.
  Medscape Medical News, June 01, 2020
• AAN 2020No Benefit of 3 Commonly Used Medications in MS Fatigue TRIUMPHANT, a new placebo-controlled trial, has not shown any benefit over placebo of three different drugs commonly used to treat fatigue in patients with multiple sclerosis.
  Medscape Medical News, May 29, 2020
• CMSC 2020Ofatumumab Shows High Elimination of Disease Activity in MS The pooled findings from the phase 3 ASCLEPIOS trials show robust efficacy of the self-injected therapy for relapsing multiple sclerosis.
  Medscape Medical News, May 29, 2020
• CMSC 2020Natalizumab Switch to Moderate-Efficacy DMT Ups Disability Risk Patients who switched to another high-efficacy therapy had improved disability and inflammatory outcomes.
  Medscape Medical News, May 27, 2020
• EAN 2020High Levels of Air Pollution Linked to Increased MS Risk Living in highly polluted urban areas is associated with a greater risk of developing multiple sclerosis than living in less polluted areas, a large population-based study suggests.
  Medscape Medical News, May 27, 2020
• Study Confirms Higher Risk of Inflammatory CNS Events With Some TNF Inhibitors Exposure to TNF inhibitors is associated with an increased risk of inflammatory events in the CNS in patients with autoimmune diseases, according to a retrospective study.
  Reuters Health Information, May 25, 2020
• AAN 2020Natalizumab Bests Fingolimod for Relapsing-Remitting MS In a head-to-head comparison, natalizumab was superior to fingolimod for evidence of disease activity at 1 year for patients with active relapsing-remitting multiple sclerosis.
  Medscape Medical News, May 13, 2020
• Multiple Sclerosis Tied to Increased Risk for Stroke, CVD, Death Patients with MS have a significantly increased risk for stroke, cardiovascular disease, and mortality. The finding points to the need for early and aggressive lifestyle interventions.
  Medscape Medical News, May 12, 2020
• AAN 2020Depression Linked to Neuro Dysfunction, Brain Lesions in MS Depression is associated with decreased neuroperformance and increased likelihood of new brain lesions in patients with multiple sclerosis, a new study of more than 2500 participants suggests.
  Medscape Medical News, May 12, 2020
• Rituximab Promising in New-Onset Myasthenia Gravis New research suggests rituximab is safer and more effective than immunosuppressants for myasthenia gravis, especially in new-onset disease.
  Medscape Medical News, May 11, 2020
• 'Reassuring' Study Examines COVID-19 Risk in MS In a new study, Italian researchers analyzed how hundreds of people with multiple sclerosis fared following infection with the novel coronavirus.
  Medscape Medical News, May 08, 2020
• AAN 2020Serum NfL in Early MS Can Help Predict Clinical Course Levels of serum NfL around the time of MS onset are associated with long-term clinical disease progression, with more rapid progression seen with higher baseline levels.
  Medscape Medical News, May 06, 2020
• AAN 2020Cautionary Findings on Immunodeficiency From Anti-CD20 MS Therapy In a study of 527 randomly selected patients with MS on anti-CD20 medications, 38% developed low immunoglobulin M and 7.4% developed hypogammaglobulinemia during a mean 30 months of follow-up.
  Medscape Medical News, May 05, 2020
• AAN 2020Initial High-Efficacy MS Therapy Tied to Less Disability Later Aggressively treating multiple sclerosis early in the course of disease is associated with lower disability a decade later, new research suggest. But there's a trade-off.
  Medscape Medical News, May 05, 2020
• AAN 2020Five-Year Siponimod Data Support Early MS Treatment Progression of disability was less likely and the annualized relapse rate was lower for patients who received with siponimod throughout the study.
  Medscape Medical News, May 04, 2020
• Alert EMA Panel Backs Generic for MS Drug Fingolimod (Gilenya) Studies have demonstrated bioequivalence of Fingolimod Accord to the reference product Gilenya for relapsing forms of multiple sclerosis, the EMA said.
  News Alerts, May 01, 2020
• AAN 2020Report Details First Case of PML With Ocrelizumab Alone The first case of progressive multifocal leukoencephalopathy directly associated with ocrelizumab occurred in a patient with primary progressive MS who received 2 years of ocrelizumab monotherapy.
  Medscape Medical News, April 30, 2020
• Trials and Tribulations: Neurology Research During COVID-19 Investigators leading ongoing pivotal trials in Alzheimer's, multiple sclerosis, and stroke have had to make a quick pivot to change plans and protocols for key trials during the COVID-19 pandemic.
  Medscape Medical News, April 29, 2020
• Joint ACTRIMS/ECTRIMS Conference Still a Go Despite Pandemic Despite the challenges of the COVID-19 pandemic, leaders at ACTRIMS and ECTRIMS remain determined to conduct their major joint conference this Fall.
  Medscape Medical News, April 22, 2020